
1. General Information
Ibyra 150mg Tablet is an oral anticancer medicine containing Olaparib 150mg. It is a targeted therapy known as a PARP (poly ADP-ribose polymerase) inhibitor. PARP enzymes participate in repairing damaged DNA. Blocking this repair pathway can cause certain cancer cells, particularly those with defects in other DNA-repair mechanisms such as BRCA-related pathways, to accumulate DNA damage and die.
Ibyra is generally prescribed when its use is appropriate for the patient's specific cancer type, treatment history, and biomarker/genetic status.
2. Product Information
- Brand Name: Ibyra 150mg Tablet
- Active Ingredient: Olaparib
- Strength: 150mg
- Dosage Form: Oral tablet
- Therapeutic Class: Anticancer medicine
- Drug Class: PARP inhibitor
- Manufacturer/Marketer: Zydus Healthcare / Zydus Cadila
- Typical Pack Information: 60 tablets per bottle, according to Indian product listings
- Prescription Status: Prescription medicine
- Country of Origin: India
3. Uses of Ibyra 150mg
Olaparib is used for selected patients with certain types of:
Ovarian Cancer
It can be used in maintenance treatment of certain advanced ovarian, fallopian-tube, or primary peritoneal cancers, particularly following a response to platinum-based chemotherapy and when relevant molecular criteria are present.
Breast Cancer
It may be prescribed for selected HER2-negative breast cancers associated with BRCA mutations, depending on disease stage and treatment history.
Pancreatic Cancer
Olaparib may be used as maintenance treatment in selected patients with metastatic pancreatic cancer associated with inherited BRCA mutations following response to platinum-based chemotherapy.
Prostate Cancer
It may be used for selected patients with metastatic castration-resistant prostate cancer having particular DNA-repair gene alterations.
The exact indication depends on the patient's diagnosis, genetic/biomarker testing, previous treatment, and local prescribing guidelines.
4. Benefits of Ibyra 150mg
Ibyra 150mg may provide the following therapeutic benefits when appropriately prescribed:
- Provides targeted anticancer treatment through PARP inhibition.
- Interferes with DNA-repair mechanisms that certain cancer cells depend upon.
- May help slow cancer progression in patients whose cancers are appropriate for olaparib treatment.
- Can be used as maintenance therapy in certain cancers after an initial response to chemotherapy.
- Provides an oral treatment option that can be incorporated into an oncologist-directed treatment plan.
The expected benefit varies considerably according to cancer type, genetic mutations, previous treatments, and individual patient factors.
5. Side Effects of Ibyra 150mg
Like other anticancer medicines, Ibyra can cause side effects. Not every patient experiences them, and their severity can vary.
Possible side effects include:
- Nausea
- Vomiting
- Fatigue or weakness
- Anemia
- Decreased white blood cell counts
- Decreased platelet counts
- Diarrhea
- Loss of appetite
- Headache
- Dizziness
- Abdominal discomfort
- Indigestion
- Taste changes
- Cough or breathlessness
Rare but potentially serious complications include significant blood-cell abnormalities, pneumonitis/interstitial lung disease, and myelodysplastic syndrome/acute myeloid leukemia. Unusual or severe symptoms require prompt medical evaluation.
6. Common Side Effects
The commonly reported side effects of Ibyra/Olaparib include:
- Nausea
- Fatigue
- Vomiting
- Anemia
- Loss of appetite
- Diarrhea
- Headache
- Reduced blood-cell counts
- Abdominal discomfort
- Taste changes
If side effects are persistent, severe, or interfere with normal activities, the treating doctor should be contacted.
7. How to Use Ibyra 150mg
- Take Ibyra exactly as prescribed by your oncologist.
- The 150mg tablet should be swallowed whole with water.
- Do not crush, chew, or split the tablet.
- It can generally be taken with or without food.
- Try to take doses at approximately the same times each day.
- Do not change the dose or stop treatment without consulting your doctor.
- If a dose is missed, follow your doctor's/pharmacist's instructions rather than taking an extra dose.
The 150mg strength does not by itself determine the patient's daily dose. Olaparib dosing can differ according to the indication, kidney function, other medicines, and tolerability.
8. How Ibyra 150mg Works
Ibyra contains Olaparib, which blocks the activity of PARP enzymes involved in DNA repair.
Some cancer cells already have defects in other DNA-repair pathways, such as those associated with BRCA1/BRCA2 alterations. When PARP-mediated repair is also blocked, DNA damage can accumulate to a level that the cancer cell cannot survive.
This mechanism is often described as synthetic lethality and is the basis for the targeted action of PARP inhibitors such as olaparib.
9. Safety Advice for Ibyra 150mg
Pregnancy
Olaparib can harm an unborn baby. It should not be used during pregnancy unless specifically determined appropriate by the treating specialist. Patients who could become pregnant should discuss effective contraception with their doctor.
Breastfeeding
Breastfeeding should be avoided during treatment unless the treating physician provides specific guidance.
Blood Counts
Olaparib can reduce blood-cell counts. Doctors may recommend regular complete blood counts (CBC) during treatment to monitor for anemia, neutropenia, thrombocytopenia, or other abnormalities.
Kidney Problems
Patients with kidney impairment should tell their doctor before treatment because dose adjustment may be necessary in some circumstances.
Other Medicines
Olaparib can interact with other medicines. Inform your doctor about all prescription medicines, over-the-counter medicines, vitamins, and herbal supplements before starting treatment.
Grapefruit
Grapefruit and grapefruit juice may affect olaparib exposure and should generally be avoided unless the treating healthcare professional advises otherwise.
Lung Symptoms
Report new or worsening cough, breathing difficulty, chest discomfort, or unexplained shortness of breath promptly because rare serious lung complications can occur.
Driving
If the medicine causes dizziness, weakness, fatigue, or reduced alertness, avoid driving or operating machinery.
Storage
Keep the tablets in their original packaging, protected from excessive heat and moisture, and out of reach of children. Follow the storage instructions on the product packaging.
10. Frequently Asked Questions (FAQs)
Q1. What is Ibyra 150mg Tablet?
Ibyra 150mg is an anticancer prescription medicine containing Olaparib 150mg, a PARP inhibitor.
Q2. What is Ibyra 150mg used for?
It is used for selected ovarian, breast, pancreatic, and prostate cancers, depending on the cancer's characteristics and applicable treatment criteria.
Q3. Is Ibyra 150mg a chemotherapy medicine?
It is an anticancer medicine but belongs specifically to the PARP inhibitor/targeted therapy class rather than being a conventional cytotoxic chemotherapy drug.
Q4. How should Ibyra 150mg be taken?
Take it exactly according to the oncologist's prescription. The tablet should be swallowed whole and should not be crushed or chewed.
Q5. Can I take Ibyra with food?
Ibyra may generally be taken with or without food.
Q6. Can Ibyra 150mg be used during pregnancy?
Olaparib may cause serious harm to an unborn baby. Discuss pregnancy prevention and treatment with your oncologist before using it.
Q7. Does Ibyra require a prescription?
Yes. It is a prescription anticancer medicine and should be used under medical supervision.
Q8. What monitoring is required during treatment?
Doctors commonly monitor blood counts and may perform other tests depending on the patient's cancer, treatment plan, kidney function, and clinical condition.
Q9. What should I do if I experience severe side effects?
Contact your treating doctor promptly. Serious symptoms such as severe weakness, fever/infection symptoms, unusual bleeding, or breathing difficulty require urgent medical assessment.
Q10. Can I take other medicines with Ibyra?
Some medicines can interact with olaparib. Provide your doctor with a complete list of medicines and supplements before starting treatment.
11. Substitutes for Ibyra 150mg
Possible olaparib 150mg alternatives/brands listed in Indian medicine references include:
- Olparib 150mg Tablet – Glenmark Pharmaceuticals
- Obparp 150 Tablet – Cipla
- Lynparza 150mg Tablet – AstraZeneca
- Olabir 150mg Tablet – Aprazer Healthcare
- Obrenza 150 Tablet – Sun Pharmaceutical Industries
These products may contain the same active ingredient, Olaparib 150mg, but brand, formulation, availability, regulatory status, and pricing can differ. A substitute should not be selected or switched without approval from the treating oncologist/pharmacist.
12. Keywords
Product Keywords
- Ibyra 150mg Tablets
- Ibyra 150mg Olaparib Tablets
- Ibyra 150mg Olaparib
- Olaparib 150mg Tablets
- Olaparib 150mg medicine
- Ibyra 150mg manufacturer
- Ibyra 150mg supplier
- Ibyra 150mg exporter
- Ibyra 150mg pharmaceutical exporter
- Ibyra 150mg tablets from India
B2B / Export Keywords
- Buy Ibyra 150mg Tablets from India
- Ibyra 150mg Tablets exporter from India
- Ibyra 150mg wholesale supplier India
- Olaparib 150mg pharmaceutical exporter India
- Olaparib 150mg wholesale supplier
- Ibyra 150mg international medicine supplier
- Ibyra 150mg bulk pharmaceutical supplier
- Ibyra 150mg oncology medicine exporter
- Indian oncology medicine exporter
- anticancer medicine exporter from India
- prescription medicine exporter India
- oncology pharmaceutical supplier India
- cancer medicine wholesale supplier India
- Olaparib medicine supplier India
Location / Market Keywords
- Ibyra 150mg exporter from Nagpur India
- Ibyra 150mg supplier to USA
- Ibyra 150mg supplier to UK
- Ibyra 150mg supplier to Australia
- Ibyra 150mg supplier to Canada
- Ibyra 150mg supplier to Singapore
- Ibyra 150mg supplier to South Korea
- Ibyra 150mg supplier to UAE
- Olaparib 150mg exporter India to USA
- Olaparib 150mg exporter India to UK
- Olaparib 150mg exporter India to Australia
- Olaparib 150mg exporter India to Canada
- Olaparib 150mg exporter India to Singapore
- Olaparib 150mg exporter India to South Korea
- Olaparib 150mg exporter India to UAE
Keywords







